Waters Corporation (WAT) Stock: Price, Forecast & Analyst Target
Waters Corporation (WAT) — MoonshotScore 60/100 (Fair band), calculated Nov 18, 2026. Price $456.48 (-2.06%), as of the Nov 19, 2026 trading session; market cap $88.7B. Expected results Feb 8, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Waters Corporation · WAT · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Waters sells laboratory measurement systems, chemistry consumables, software and instrument service across pharmaceutical, life-science and industrial workflows. Its case now depends on whether a much larger reported business can convert rising sales and recurring installed-base revenue into restored accounting profit and durable cash generation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Waters (WAT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet, weak growth and an expensive valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Rich; Growth Durability: Fading; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 3.99 · Piotroski F 5
- ROE 0.8% · ROA 0.4% · current ratio 1.89 · earnings yield 0.2% · free-cash-flow yield 0.7%
Holding back: balance-sheet strain, soft growth
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 64 | Fair | |
| 64 | Fair | |
| 64 | Fair | |
| 64 | Fair | |
| 60 | Fair | |
| 60 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $456.48 | |
| Change on the day | -2.06% | |
| 52-week range | $282.77–$483.33 | |
| Market capitalisation | $88.7B | |
| Price / earnings (trailing) | 191.40 | |
| Shares traded on the day | 1.02M | |
| Beta (volatility vs the S&P 500) | 1.15 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Waters (WAT): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Waters (WAT), and what does it report?
Short answer · as of
Waters is not primarily a clinical-testing operator despite its diagnostics classification.
Research dated 2026-09-12.
It supplies the instruments and supporting products laboratories use for chromatography, mass spectrometry, thermal analysis, rheometry and calorimetry, with demand tied to research, drug development, quality control, materials testing and routine laboratory work.
Reported revenue combines Waters instrument systems, Waters service, chemistry consumables, TA instrument systems and TA service. Instrument placements create follow-on demand for columns, software and post-warranty support, so the sales mix reflects equipment purchasing alongside recurring use of an installed base.
What do the latest results show for Waters (WAT)?
Research dated 2026-09-12.
The latest reported periods show a sharp expansion in revenue alongside accounting losses, after the latest annual period had delivered higher sales and remained profitable. Gross profit grew in absolute terms, but research and selling expenses climbed far faster than their earlier quarterly run rates, leaving operating and net results below zero.
That accounting picture differs from the earnings releases, where adjusted earnings and revenue continued to exceed estimates. A filing records the completion of an acquisition, while management now frames its outlook around Biosciences and Diagnostic Solutions; management attributes the expected improvement to China localization, new commercial leadership and firmer biotech and academic demand, partly offset by currency effects.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.77B Nov 3, 2026
- Latest report · revenue estimate
- $1.75B Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $1.77B | $1.75B | $4.1000 | $4.0000 |
| Aug 4, 2026 | $1.65B | $1.62B | $3.0500 | $3.0100 |
| May 5, 2026 | $1.27B | $1.20B | $2.7000 | $2.3100 |
| Feb 9, 2026 | $932.36M | $928.34M | $4.5300 | $4.5100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $800M | $149M | $2.48 (diluted) |
| Q4 FY2025 | $932M | $225M | $3.77 (diluted) |
| Mar 2026 | $1.27B | -$72M | -$0.88 (diluted) |
| Jun 2026 | $1.65B | -$136M | -$1.38 (diluted) |
What are the financial strengths and risks for Waters (WAT)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Waters entered the change in reporting scope with a record of annual profitability and a revenue base that includes substantial service and consumables sales. Operating cash flow rebounded strongly in the latest period after slipping slightly below zero in the preceding period, and cash has risen from earlier levels despite uneven quarterly conversion.
Debt materially exceeds cash and investments, while trailing profitability and returns have fallen well below the levels implied by the prior annual record. That combination makes execution more sensitive: weak instrument demand would pressure a major revenue line, and failure to turn the enlarged cost base into profit would leave less room to absorb the debt burden. Service and chemistry consumables provide a recurring counterweight, but they do not eliminate that risk.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 191.40 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Waters (WAT)?
Short answer · as of
The next earnings report is expected on Feb 8, 2027. The number it tests is the $14.68 EPS analysts carry for it.
Research dated 2026-09-12.
The next earnings release needs to reconcile three moving pieces: management's expected organic constant-currency growth, the much larger Biosciences and Diagnostic Solutions revenue base, and the persistence of reported operating losses. Revenue meeting management's seasonal expectations would establish demand momentum; renewed accounting profit would show that expense growth is beginning to settle.
Cash conversion deserves equal weight. Sustained positive operating cash flow after capital spending, accompanied by a stable or improving cash balance, would strengthen the enlarged company's financial footing; renewed cash weakness while debt remains elevated would point the other way.
How does Waters compare with its peers?
Short answer
Waters's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Waters combines high-value analytical instruments with columns, software and post-warranty service used throughout laboratory workflows. Relative to a business dependent mainly on fresh instrument placements, its installed base can generate repeat consumables and service demand; relative to a consumables specialist, however, Waters retains meaningful exposure to laboratory capital spending.
Its breadth also extends beyond drug research and diagnostics into thermal and material characterization for polymers, metals, chemicals and viscous materials. The relevant comparison is therefore with diversified analytical-instrument suppliers, not with laboratories that perform tests or narrowly focused diagnostic vendors.
| Company | Price | Market value | Score |
|---|---|---|---|
| $689.65 Nov 19, 2026 | $54.3B | 96 5-pillar Nov 18, 2026 | |
| $1705.66 Nov 19, 2026 | $33.9B | 93 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $633.98 Nov 19, 2026 | $17.7B | 92 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $175.34 Nov 19, 2026 | $49.4B | 83 5-pillar Nov 18, 2026 | |
| $258.99 Nov 19, 2026 | $28.5B | 74 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $227.56 Nov 19, 2026 | $160B | 71 5-pillar Nov 18, 2026 | |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $151.59 Nov 19, 2026 | $16.9B | 71 5-pillar Nov 18, 2026 | |
| Waters (WAT) — this page | $456.48 | $88.7B | 60 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $400.00 – $535.00
- Consensus target
- $470.00
- Median target
- $477.50
- Revenue estimate
- $6.49B
- EPS estimate
- $14.68
Consensus record · Captured .
Measured against a quoted price of $456.48 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 8
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 1
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held WAT in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Fundsmith | Terry Smith | Q3 2026 | 7.71% | $995.87M | Held, unchanged |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.66% | $217.15M | Trimmed −70.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Waters (WAT)?
- Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference
- Simple HealthKit Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
- What Was Waters Telling You Before Its Stock Ran?
Common Questions About WAT (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do Waters instrument placements matter for service and chemistry consumables?
A placement expands the installed base that can require chromatography columns, compatible software and post-warranty support. Instrument demand therefore affects current sales and the opportunity for recurring revenue afterward.
Why did Waters report losses while adjusted earnings beat estimates?
The income statement shows sharply higher research and selling expenses during periods of much greater reported revenue, producing accounting losses. The earnings releases present adjusted earnings above estimates, so readers should track the reconciliation between adjusted performance and reported profit.
What would confirm Waters Biosciences and Diagnostic Solutions momentum?
Organic constant-currency growth consistent with management's outlook, supported by the cited China, biotech and academic channels, would confirm demand momentum. It would be more persuasive if operating profit and cash conversion improved with revenue.
How exposed is Waters to laboratory instrument spending?
Instrument systems remain a major source of revenue across the Waters and TA divisions, leaving results sensitive to laboratory purchasing cycles. Service and chemistry consumables diversify that exposure through demand associated with instruments already in use.
What is the WAT stock price today?
The last price recorded for Waters Corporation (WAT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the WAT price target?
The analyst consensus price target for Waters Corporation (WAT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold WAT
Funds in our ETF coverage that list WAT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| QSY ETF | 1.62% |